We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.15% | 97.65 | 1,190 | 13:38:19 |
From May 2019 to May 2024
LONDON--Pharmaceutical company Midatech Pharma PLC (MTPH.LN) said Wednesday that it has signed a global licensing agreement with Novartis AG (NOVN.EB) for the oncology compound panobinostat.
The company intends to develop panobinostat for the treatment of brain tumor.
Shares at 0741 GMT trading 4.4% higher at 108 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 07, 2017 03:59 ET (07:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
